Sonodynamic therapy based on combined use of low dose administration of epirubicin-incorporating drug delivery system and focused ultrasound
| Autor: | Nobutaka Abe, Nobuhiro Nishiyama, Jun Okamoto, Hiroshi Ishii, Yoshihiro Muragaki, Masanori Maeda, Hiroshi Iseki, Nakamoto Hidekazu, Kenichi Kawabata, Shin-ichiro Umemura, Shin Yoshizawa, Kazunori Kataoka |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Drug
Oncology medicine.medical_specialty Acoustics and Ultrasonics Anthracycline Colorectal cancer Ultrasonic Therapy media_common.quotation_subject Biophysics 01 natural sciences Mice 03 medical and health sciences Drug Delivery Systems 0302 clinical medicine In vivo Pancreatic cancer Internal medicine 0103 physical sciences Animals Medicine Radiology Nuclear Medicine and imaging Epirubicin media_common 010302 applied physics Antibiotics Antineoplastic Dose-Response Relationship Drug Radiological and Ultrasound Technology business.industry Sonodynamic therapy medicine.disease Combined Modality Therapy Surgery 030220 oncology & carcinogenesis Models Animal Drug delivery business medicine.drug |
| Zdroj: | Ultrasound Med. Biol.. 43(No. 10):2295-2301 |
| Popis: | Sonodynamic therapy (SDT) is currently considered as one of the promising minimally invasive treatment options for solid cancers. SDT is based on the combined use of a sonosensitizer drug and high-intensity focused ultrasound (HIFU) to produce cytotoxic reactive oxygen species (ROS) in and around neoplastic cells. Anthracycline drugs, including epirubicin (EPI), have been well known as effective sonosensitizers after interaction with focused ultrasound. Recently a new anticancer drug delivery system (DDS), NC-6300, has been developed that comprises EPI through an acid–labile hydrazone bond. In previous in vivo studies, NC-6300 showed basic drug safety and an excellent concentration property of EPI, and recently has been tested in clinical trials. For realizing minimally invasive cancer treatment, the present study demonstrated the effectiveness and feasibility of DDS-based SDT, which combined a small dose of NC-6300 and low energy of HIFU in mouse models of colon cancer and pancreatic cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|